Publications by Nina Iversen

56 publications found

1. Iversen N, Henriksson CE, Sletten M, Le MS, Lindberg BR, Andersen R, Paus B (2024)
   Heterozygosity for the Budapest 3 mutation in SERPINC1 in a family with thrombophilia and structural anomalies of the inferior vena cava
   Thromb J, 22 (1), 75
   DOI 10.1186/s12959-024-00644-1, PubMed 39129027
2. Sletten M, Skogstrøm KB, Lind SM, Tinholt M, Stavik B, Rayner S, Iversen N (2024)
   Elevated TFPI is a prognostic factor in hepatocellular carcinoma: Putative role of miR-7-5p and miR-1236-3p
   Thromb Res, 241, 109073
   DOI 10.1016/j.thromres.2024.109073, PubMed 38945092
3. Lind SM, Sletten M, Hellenes M, Mathelier A, Tekpli X, Tinholt M, Iversen N (2024)
   Coagulation factor V in breast cancer: a p53-regulated tumor suppressor and predictive marker for treatment response to chemotherapy
   J Thromb Haemost, 22 (6), 1569-1582
   DOI 10.1016/j.jtha.2024.02.008, PubMed 38382738
4. Tinholt M, Tekpli X, Torland LA, Tahiri A, Geisler J, Kristensen V, Sandset PM, Iversen N (2024)
   The breast cancer coagulome in the tumor microenvironment and its role in prognosis and treatment response to chemotherapy
   J Thromb Haemost, 22 (5), 1319-1335
   DOI 10.1016/j.jtha.2024.01.003, PubMed 38237862
5. Bassi N, Hovland HN, Rasheed K, Jarhelle E, Pedersen N, Mchaina EK, Bakkan SME, Iversen N, Høberg-Vetti H, Haukanes BI, Knappskog PM, Aukrust I, Ognedal E, Van Ghelue M (2023)
   Functional analyses of rare germline BRCA1 variants by transcriptional activation and homologous recombination repair assays
   BMC Cancer, 23 (1), 368
   DOI 10.1186/s12885-023-10790-w, PubMed 37085799
6. de la Morena-Barrio ME, Suchon P, Jacobsen EM, Iversen N, Miñano A, de la Morena-Barrio B, Bravo-Pérez C, Padilla J, Cifuentes R, Asenjo S, Deleuze JF, Trégouët DA, Lozano ML, Vicente V, Sandset PM, Morange PE, Corral J (2022)
   Two SERPINC1 variants affecting N-glycosylation of Asn224 cause severe thrombophilia not detected by functional assays
   Blood, 140 (2), 140-151
   DOI 10.1182/blood.2021014708, PubMed 35486842
7. Andresen MS, Sletten M, Sandset PM, Iversen N, Stavik B, Tinholt M (2021)
   Coagulation Factor V (F5) is an Estrogen-Responsive Gene in Breast Cancer Cells
   Thromb Haemost, 122 (8), 1288-1295
   DOI 10.1055/a-1707-2130, PubMed 34826880
8. Fiskvik H, Jacobsen AF, Iversen N, Henriksson CE, Jacobsen EM (2021)
   Treatment of Homozygous Type II Antithrombin Heparin-Binding Site Deficiency in Pregnancy
   Case Rep Obstet Gynecol, 2021, 4393821
   DOI 10.1155/2021/4393821, PubMed 34513101
9. Andersen E, Chollet ME, Sletten M, Stavik B, Skarpen E, Backe PH, Thiede B, Glosli H, Henriksson CE, Iversen N (2021)
   Molecular Characterization of Two Homozygous Factor VII Variants Associated with Intracranial Bleeding
   Thromb Haemost, 121 (12), 1588-1598
   DOI 10.1055/a-1450-8568, PubMed 33742435
10. Cui XY, Tjønnfjord GE, Kanse SM, Dahm AEA, Iversen N, Myklebust CF, Sun L, Jiang ZX, Ueland T, Campbell JJ, Ho M, Sandset PM (2021)
    Tissue factor pathway inhibitor upregulates CXCR7 expression and enhances CXCL12-mediated migration in chronic lymphocytic leukemia
    Sci Rep, 11 (1), 5127
    DOI 10.1038/s41598-021-84695-8, PubMed 33664415
11. Tinholt M, Stavik B, Tekpli X, Garred Ø, Borgen E, Kristensen V, Sahlberg KK, Sandset PM, Iversen N (2020)
    Coagulation factor V is a marker of tumor-infiltrating immune cells in breast cancer
    Oncoimmunology, 9 (1), 1824644
    DOI 10.1080/2162402X.2020.1824644, PubMed 33457104
12. Andresen MS, Stavik B, Sletten M, Tinholt M, Sandset PM, Iversen N, Skretting G (2020)
    Indirect regulation of TFPI-2 expression by miR-494 in breast cancer cells
    Sci Rep, 10 (1), 4036
    DOI 10.1038/s41598-020-61018-x, PubMed 32132611
13. Skretting G, Andersen E, Myklebust CF, Sandset PM, Tinholt M, Iversen N, Stavik B (2019)
    Transcription factor FOXP3: A repressor of the TFPI gene?
    J Cell Biochem, 120 (8), 12924-12936
    DOI 10.1002/jcb.28563, PubMed 30861202
14. Langerud J, Jarhelle E, Van Ghelue M, Ariansen SL, Iversen N (2018)
    Trans-activation-based risk assessment of BRCA1 BRCT variants with unknown clinical significance
    Hum Genomics, 12 (1), 51
    DOI 10.1186/s40246-018-0183-1, PubMed 30458859
15. Tinholt M, Garred Ø, Borgen E, Beraki E, Schlichting E, Kristensen V, Sahlberg KK, Iversen N (2018)
    Subtype-specific clinical and prognostic relevance of tumor-expressed F5 and regulatory F5 variants in breast cancer: the CoCaV study
    J Thromb Haemost, 16 (7), 1347-1356
    DOI 10.1111/jth.14151, PubMed 29766637
16. Cui XY, Skretting G, Tinholt M, Stavik B, Dahm AEA, Sahlberg KK, Kanse S, Iversen N, Sandset PM (2017)
    A novel hypoxia response element regulates oxygen-related repression of tissue factor pathway inhibitor in the breast cancer cell line MCF-7
    Thromb Res, 157, 111-116
    DOI 10.1016/j.thromres.2017.07.013, PubMed 28734156
17. Stavik B, Holm S, Espada S, Iversen N, Sporsheim B, Bjerkeli V, Dahl TB, Sandset PM, Skjelland M, Espevik T, Skretting G, Halvorsen B (2017)
    Increased expression of TFPI in human carotid stenosis
    Thromb Res, 155, 31-37
    DOI 10.1016/j.thromres.2017.04.024, PubMed 28482260
18. Andresen MS, Ali HO, Myklebust CF, Sandset PM, Stavik B, Iversen N, Skretting G (2017)
    Estrogen induced expression of tissue factor pathway inhibitor-2 in MCF7 cells involves lysine-specific demethylase 1
    Mol Cell Endocrinol, 443, 80-88
    DOI 10.1016/j.mce.2017.01.016, PubMed 28088469
19. Tinholt M, Sandset PM, Mowinckel MC, Garred Ø, Sahlberg KK, Kristensen VN, Børresen-Dale AL, Jacobsen AF, Skretting G, Iversen N (2016)
    Determinants of acquired activated protein C resistance and D-dimer in breast cancer
    Thromb Res, 145, 78-83
    DOI 10.1016/j.thromres.2016.08.003, PubMed 27505249
20. Tinholt M, Sandset PM, Iversen N (2016)
    Polymorphisms of the coagulation system and risk of cancer
    Thromb Res, 140 Suppl 1, S49-54
    DOI 10.1016/S0049-3848(16)30098-6, PubMed 27067978
21. Ali HO, Stavik B, Myklebust CF, Andersen E, Dahm AE, Iversen N, Sandset PM, Skretting G (2016)
    Oestrogens Downregulate Tissue Factor Pathway Inhibitor through Oestrogen Response Elements in the 5'-Flanking Region
    PLoS One, 11 (3), e0152114
    DOI 10.1371/journal.pone.0152114, PubMed 26999742
22. Ali HO, Arroyo AB, González-Conejero R, Stavik B, Iversen N, Sandset PM, Martínez C, Skretting G (2016)
    The role of microRNA-27a/b and microRNA-494 in estrogen-mediated downregulation of tissue factor pathway inhibitor α
    J Thromb Haemost, 14 (6), 1226-37
    DOI 10.1111/jth.13321, PubMed 26999003
23. Stavik B, Espada S, Cui XY, Iversen N, Holm S, Mowinkel MC, Halvorsen B, Skretting G, Sandset PM (2016)
    EPAS1/HIF-2 alpha-mediated downregulation of tissue factor pathway inhibitor leads to a pro-thrombotic potential in endothelial cells
    Biochim Biophys Acta, 1862 (4), 670-678
    DOI 10.1016/j.bbadis.2016.01.017, PubMed 26826018
24. Cui XY, Tinholt M, Stavik B, Dahm AE, Kanse S, Jin Y, Seidl S, Sahlberg KK, Iversen N, Skretting G, Sandset PM (2016)
    Effect of hypoxia on tissue factor pathway inhibitor expression in breast cancer
    J Thromb Haemost, 14 (2), 387-96
    DOI 10.1111/jth.13206, PubMed 26598923
25. Chollet ME, Skarpen E, Iversen N, Sandset PM, Skretting G (2015)
    The chemical chaperone sodium 4-phenylbutyrate improves the secretion of the protein CA267T mutant in CHO-K1 cells trough the GRASP55 pathway
    Cell Biosci, 5, 57
    DOI 10.1186/s13578-015-0048-4, PubMed 26457178
26. Tinholt M, Vollan HK, Sahlberg KK, Jernström S, Kaveh F, Lingjærde OC, Kåresen R, Sauer T, Kristensen V, Børresen-Dale AL, Sandset PM, Iversen N (2015)
    Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF
    Breast Cancer Res, 17 (1), 44
    DOI 10.1186/s13058-015-0548-5, PubMed 25882602
27. Tinholt M, Stavik B, Louch W, Carlson CR, Sletten M, Ruf W, Skretting G, Sandset PM, Iversen N (2015)
    Syndecan-3 and TFPI colocalize on the surface of endothelial-, smooth muscle-, and cancer cells
    PLoS One, 10 (1), e0117404
    DOI 10.1371/journal.pone.0117404, PubMed 25617766
28. Tinholt M, Viken MK, Dahm AE, Vollan HK, Sahlberg KK, Garred O, Børresen-Dale AL, Jacobsen AF, Kristensen V, Bukholm I, Kåresen R, Schlichting E, Skretting G, Lie BA, Sandset PM, Iversen N (2014)
    Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study
    BMC Cancer, 14, 845
    DOI 10.1186/1471-2407-14-845, PubMed 25407022
29. Ali HO, Stavik B, Dørum E, Iversen N, Sandset PM, Skretting G (2014)
    Oestrogen induced downregulation of TFPI expression is mediated by ERα
    Thromb Res, 134 (1), 138-43
    DOI 10.1016/j.thromres.2014.04.004, PubMed 24785473
30. Askautrud HA, Gjernes E, Gunnes G, Sletten M, Ross DT, Børresen-Dale AL, Iversen N, Tranulis MA, Frengen E (2014)
    Global gene expression analysis reveals a link between NDRG1 and vesicle transport
    PLoS One, 9 (1), e87268
    DOI 10.1371/journal.pone.0087268, PubMed 24498060
31. Stavik B, Tinholt M, Sletten M, Skretting G, Sandset PM, Iversen N (2013)
    TFPIα and TFPIβ are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity
    J Hematol Oncol, 6, 5
    DOI 10.1186/1756-8722-6-5, PubMed 23320987
32. Stavik B, Skretting G, Olstad OK, Sletten M, Dehli Vigeland M, Sandset PM, Iversen N (2012)
    TFPI alpha and beta regulate mRNAs and microRNAs involved in cancer biology and in the immune system in breast cancer cells
    PLoS One, 7 (10), e47184
    DOI 10.1371/journal.pone.0047184, PubMed 23071754
33. Skretting G, Iversen N, Myklebust CF, Dahm AE, Sandset PM (2012)
    Overexpression of tissue factor pathway inhibitor in CHO-K1 cells results in increased activation of NF-κB and apoptosis mediated by a caspase-3 independent pathway
    Mol Biol Rep, 39 (12), 10089-96
    DOI 10.1007/s11033-012-1882-7, PubMed 22932941
34. Brandt C, Jakobsen AH, Adser H, Olesen J, Iversen N, Kristensen JM, Hojman P, Wojtaszewski JF, Hidalgo J, Pilegaard H (2011)
    IL-6 regulates exercise and training-induced adaptations in subcutaneous adipose tissue in mice
    Acta Physiol (Oxf), 205 (2), 224-35
    DOI 10.1111/j.1748-1716.2011.02373.x, PubMed 21991887
35. Tjeldhorn L, Iversen N, Sandvig K, Bergan J, Sandset PM, Skretting G (2011)
    Protein C mutation (A267T) results in ER retention and unfolded protein response activation
    PLoS One, 6 (8), e24009
    DOI 10.1371/journal.pone.0024009, PubMed 21901152
36. Stavik B, Skretting G, Aasheim HC, Tinholt M, Zernichow L, Sletten M, Sandset PM, Iversen N (2011)
    Downregulation of TFPI in breast cancer cells induces tyrosine phosphorylation signaling and increases metastatic growth by stimulating cell motility
    BMC Cancer, 11, 357
    DOI 10.1186/1471-2407-11-357, PubMed 21849050
37. Kostovski E, Dahm AE, Iversen N, Hjeltnes N, Østerud B, Sandset PM, Iversen PO (2011)
    Melatonin stimulates release of tissue factor pathway inhibitor from the vascular endothelium
    Blood Coagul Fibrinolysis, 22 (4), 254-9
    DOI 10.1097/MBC.0b013e3283442ce2, PubMed 21297449
38. Stavik B, Skretting G, Sletten M, Sandset PM, Iversen N (2010)
    Overexpression of both TFPIα and TFPIβ induces apoptosis and expression of genes involved in the death receptor pathway in breast cancer cells
    Mol Carcinog, 49 (11), 951-63
    DOI 10.1002/mc.20679, PubMed 20886581
39. Tjeldhorn L, Iversen N, Sandvig K, Bergan J, Sandset PM, Skretting G (2010)
    Functional characterization of the protein C A267T mutation: evidence for impaired secretion due to defective intracellular transport
    BMC Cell Biol, 11, 67
    DOI 10.1186/1471-2121-11-67, PubMed 20815936
40. Roslev P, Bukh AS, Iversen L, Sønderbo H, Iversen N (2010)
    Application of mussels as biosamplers for characterization of faecal pollution in coastal recreational waters
    Water Sci Technol, 62 (3), 586-93
    DOI 10.2166/wst.2010.910, PubMed 20706005
41. Skretting G, Stavik B, Landvik NE, Myklebust CF, Iversen N, Zienolddiny S, Sandset PM (2010)
    Functional characterization of polymorphisms in the human TFPI gene
    Biochem Biophys Res Commun, 397 (1), 106-11
    DOI 10.1016/j.bbrc.2010.05.078, PubMed 20519147
42. Roslev P, Iversen L, Sønderbo HL, Iversen N, Bastholm S (2009)
    Uptake and persistence of human associated Enterococcus in the mussel Mytilus edulis: relevance for faecal pollution source tracking
    J Appl Microbiol, 107 (3), 944-53
    DOI 10.1111/j.1365-2672.2009.04272.x, PubMed 19486428
43. Negaard HF, Svennevig K, Kolset SO, Iversen N, Lothe IM, Østenstad B, Sandset PM, Iversen PO (2009)
    Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas
    Leuk Lymphoma, 50 (6), 998-1004
    DOI 10.1080/10428190902889270, PubMed 19373600
44. Skretting G, Lien T, Sandset PM, Iversen N (2008)
    Expression of the V264M TFPI mutant in endothelial cell cultures may involve mRNA stability
    Thromb Res, 123 (6), 851-5
    DOI 10.1016/j.thromres.2008.09.003, PubMed 19007969
45. Negaard HF, Iversen N, Bowitz-Lothe IM, Sandset PM, Steinsvik B, Ostenstad B, Iversen PO (2008)
    Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors
    Leukemia, 23 (1), 162-9
    DOI 10.1038/leu.2008.255, PubMed 18800145
46. Negaard HF, Iversen PO, Østenstad B, Iversen N, Holme PA, Sandset PM (2008)
    Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor
    Thromb Haemost, 99 (6), 1040-8
    DOI 10.1160/TH07-09-0541, PubMed 18521506
47. Dahm AE, Iversen N, Birkenes B, Ree AH, Sandset PM (2006)
    Estrogens, selective estrogen receptor modulators, and a selective estrogen receptor down-regulator inhibit endothelial production of tissue factor pathway inhibitor 1
    BMC Cardiovasc Disord, 6, 40
    DOI 10.1186/1471-2261-6-40, PubMed 17029634
48. Brodin E, Iversen N, Hansen JB (2006)
    Impact of native VLDL on tissue factor pathway inhibitor in endothelial cells and interactions between TFPI and lipoprotein lipase
    J Lab Clin Med, 147 (4), 167-73
    DOI 10.1016/j.lab.2005.11.010, PubMed 16581344
49. Iversen N, Birkenes B, Torsdalen K, Djurovic S (2005)
    Electroporation by nucleofector is the best nonviral transfection technique in human endothelial and smooth muscle cells
    Genet Vaccines Ther, 3 (1), 2
    DOI 10.1186/1479-0556-3-2, PubMed 15836781
50. Djurovic S, Iversen N, Jeansson S, Hoover F, Christensen G (2004)
    Comparison of nonviral transfection and adeno-associated viral transduction on cardiomyocytes
    Mol Biotechnol, 28 (1), 21-32
    DOI 10.1385/MB:28:1:21, PubMed 15456960
51. Iversen N, Brandtzaeg P, Sandset PM, Kierulf P, Abildgaard U (2002)
    TFPI fractions in plasma from patients with systemic meningococcal disease
    Thromb Res, 108 (5-6), 347-53
    DOI 10.1016/s0049-3848(03)00065-3, PubMed 12676197
52. Andresen MS, Iversen N, Abildgaard U (2002)
    Overall haemostasis potential assays performed in thrombophilic plasma: the effect of preactivating protein C and antithrombin
    Thromb Res, 108 (5-6), 323-8
    DOI 10.1016/s0049-3848(03)00067-7, PubMed 12676193
53. Iversen N, Lindahl AK, Abildgaard U (2002)
    Elevated plasma levels of the factor Xa-TFPI complex in cancer patients
    Thromb Res, 105 (1), 33-6
    DOI 10.1016/s0049-3848(01)00404-2, PubMed 11864704
54. Iversen N, Strekerud FG, Abildgaard U (2000)
    Tissue factor pathway inhibitor (TFPI) in disseminated intravascular coagulation: low levels of the activated factor X-TFPI complex
    Blood Coagul Fibrinolysis, 11 (7), 591-8
    DOI 10.1097/00001721-200010000-00002, PubMed 11085278
55. Iversen N, Lindahl AK, Abildgaard U (1998)
    Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation
    Br J Haematol, 102 (4), 889-95
    DOI 10.1046/j.1365-2141.1998.00875.x, PubMed 9734635
56. Iversen N, Sandset PM, Abildgaard U, Torjesen PA (1996)
    Binding of tissue factor pathway inhibitor to cultured endothelial cells-influence of glycosaminoglycans
    Thromb Res, 84 (4), 267-78
    DOI 10.1016/s0049-3848(96)00186-7, PubMed 8948051